JPWO2020002950A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020002950A5 JPWO2020002950A5 JP2020570716A JP2020570716A JPWO2020002950A5 JP WO2020002950 A5 JPWO2020002950 A5 JP WO2020002950A5 JP 2020570716 A JP2020570716 A JP 2020570716A JP 2020570716 A JP2020570716 A JP 2020570716A JP WO2020002950 A5 JPWO2020002950 A5 JP WO2020002950A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- groups
- optionally substituted
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000001153 fluoro group Chemical group F* 0.000 claims 30
- 206010012289 Dementia Diseases 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 208000018737 Parkinson disease Diseases 0.000 claims 14
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 13
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 13
- 230000001771 impaired effect Effects 0.000 claims 13
- -1 methylene dioxy Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 230000011664 signaling Effects 0.000 claims 13
- 208000024827 Alzheimer disease Diseases 0.000 claims 12
- 206010010774 Constipation Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 208000010877 cognitive disease Diseases 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 230000001228 trophic effect Effects 0.000 claims 7
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 208000005264 motor neuron disease Diseases 0.000 claims 6
- 235000003170 nutritional factors Nutrition 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000026072 Motor neurone disease Diseases 0.000 claims 4
- 206010039966 Senile dementia Diseases 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 208000018631 connective tissue disease Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 210000005036 nerve Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000034799 Tauopathies Diseases 0.000 claims 2
- 206010043248 Tendon rupture Diseases 0.000 claims 2
- 208000010641 Tooth disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- JJDNQLAPHDJWFS-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[3-(2-oxo-2-pyrazol-1-ylethoxy)-4-phenoxyphenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC=1C=C(C=CC=1)N1C(N(C(NC1=O)=O)C1=CC(=C(C=C1)OC1=CC=CC=C1)OCC(N1N=CC=C1)=O)=O JJDNQLAPHDJWFS-UHFFFAOYSA-N 0.000 claims 1
- USPQGSLCSUSZFA-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[4-phenoxy-3-(pyrazol-1-ylmethyl)phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(N=CC=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 USPQGSLCSUSZFA-UHFFFAOYSA-N 0.000 claims 1
- CUAHCQLIBGVRBA-UHFFFAOYSA-N 1-[3-(1H-imidazol-2-ylmethoxy)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1NC(=NC=1)COC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 CUAHCQLIBGVRBA-UHFFFAOYSA-N 0.000 claims 1
- NRFAHLSXMNUHPC-UHFFFAOYSA-N 1-[3-(1H-imidazol-5-ylmethoxy)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1NC(=CN=1)COC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 NRFAHLSXMNUHPC-UHFFFAOYSA-N 0.000 claims 1
- XQFMXUKPUWDHOG-UHFFFAOYSA-N 1-[3-(4-methylimidazol-1-yl)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound N=1C(=CN(C=1)C1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1)C XQFMXUKPUWDHOG-UHFFFAOYSA-N 0.000 claims 1
- MATQYORSAHORSS-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 MATQYORSAHORSS-UHFFFAOYSA-N 0.000 claims 1
- CQJJXUXNSYKFHP-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-(4-methoxyphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=C(OC)C=C2)=C1 CQJJXUXNSYKFHP-UHFFFAOYSA-N 0.000 claims 1
- HRSNJQDFWWOWDZ-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound N1(C=NC=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O HRSNJQDFWWOWDZ-UHFFFAOYSA-N 0.000 claims 1
- MHRFHKLSJHQLEJ-UHFFFAOYSA-N 1-[3-[(1-ethylpyrazol-4-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)N1N=CC(=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O MHRFHKLSJHQLEJ-UHFFFAOYSA-N 0.000 claims 1
- UXUIPEUVVIPUAZ-UHFFFAOYSA-N 1-[3-[(4-ethylpyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O UXUIPEUVVIPUAZ-UHFFFAOYSA-N 0.000 claims 1
- WNJCHHFPZKIZCA-UHFFFAOYSA-N 1-[3-[(4-ethylpyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O WNJCHHFPZKIZCA-UHFFFAOYSA-N 0.000 claims 1
- NFTSSKBOHVTYGA-UHFFFAOYSA-N 1-[3-[(4-fluoroimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O NFTSSKBOHVTYGA-UHFFFAOYSA-N 0.000 claims 1
- HBCCFDWBAPVQDO-UHFFFAOYSA-N 1-[3-[(4-fluoropyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O HBCCFDWBAPVQDO-UHFFFAOYSA-N 0.000 claims 1
- MCGWGLDGKHMQGB-UHFFFAOYSA-N 1-[3-[(4-fluoropyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O MCGWGLDGKHMQGB-UHFFFAOYSA-N 0.000 claims 1
- AXXSGYLDABJVJT-UHFFFAOYSA-N 1-[3-[(4-methylimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound CC=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O AXXSGYLDABJVJT-UHFFFAOYSA-N 0.000 claims 1
- CIGXRYZOSNICGE-UHFFFAOYSA-N 1-[3-[(5-methylimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CN=CN1CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O CIGXRYZOSNICGE-UHFFFAOYSA-N 0.000 claims 1
- IYFFSVLCAWSOHY-UHFFFAOYSA-N 1-[3-[[4-(difluoromethyl)imidazol-1-yl]methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC(C=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O)F IYFFSVLCAWSOHY-UHFFFAOYSA-N 0.000 claims 1
- OSCXEQPBXJAEPZ-UHFFFAOYSA-N 1-[4-(4-ethylphenoxy)-3-(pyrazol-1-ylmethyl)phenyl]-3-methyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C1=CC=C(OC2=C(C=C(C=C2)N2C(N(C(NC2=O)=O)C)=O)CN2N=CC=C2)C=C1 OSCXEQPBXJAEPZ-UHFFFAOYSA-N 0.000 claims 1
- JHKMYLLMMBBDKE-UHFFFAOYSA-N 1-[4-phenoxy-3-(1,2,4-triazol-1-ylmethyl)phenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound O(C1=CC=CC=C1)C1=C(C=C(C=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O)CN1N=CN=C1 JHKMYLLMMBBDKE-UHFFFAOYSA-N 0.000 claims 1
- XDEFQYLLZMGLKN-UHFFFAOYSA-N 1-[4-phenoxy-3-(pyrazol-1-ylmethyl)phenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound O(C1=CC=CC=C1)C1=C(C=C(C=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O)CN1N=CC=C1 XDEFQYLLZMGLKN-UHFFFAOYSA-N 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- KGUXEQIFZMEAHW-UHFFFAOYSA-N 1-methyl-3-[4-phenyl-3-(pyrazol-1-ylmethyl)phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CN1C(N(C(NC1=O)=O)C1=CC(=C(C=C1)C1=CC=CC=C1)CN1N=CC=C1)=O KGUXEQIFZMEAHW-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- VMVZGGPZNHFGKS-UHFFFAOYSA-N ethyl n-(oxomethylidene)carbamate Chemical compound CCOC(=O)N=C=O VMVZGGPZNHFGKS-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810668.2A GB201810668D0 (en) | 2018-06-28 | 2018-06-28 | New compounds |
| GB1810668.2 | 2018-06-28 | ||
| PCT/GB2019/051853 WO2020002950A1 (en) | 2018-06-28 | 2019-06-28 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529168A JP2021529168A (ja) | 2021-10-28 |
| JPWO2020002950A5 true JPWO2020002950A5 (enExample) | 2022-06-30 |
| JP7510358B2 JP7510358B2 (ja) | 2024-07-03 |
Family
ID=63143731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570716A Active JP7510358B2 (ja) | 2018-06-28 | 2019-06-28 | Ｔｒｋ受容体の調節剤としての４－置換フェニル－１，３，５－トリアジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11840524B2 (enExample) |
| EP (1) | EP3814335B1 (enExample) |
| JP (1) | JP7510358B2 (enExample) |
| KR (1) | KR20210024531A (enExample) |
| CN (1) | CN112513032B (enExample) |
| BR (1) | BR112020026619A2 (enExample) |
| CA (1) | CA3104237A1 (enExample) |
| ES (1) | ES2935183T3 (enExample) |
| GB (1) | GB201810668D0 (enExample) |
| WO (1) | WO2020002950A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008816A (es) | 2018-02-26 | 2020-09-28 | AlzeCure Pharma AB | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CA3180846A1 (en) * | 2020-06-03 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
| WO2025232990A1 (en) | 2024-05-09 | 2025-11-13 | AlzeCure Pharma AB | Triazinone derivatives for use in the treatment of inflammation |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2246109A1 (de) | 1972-09-20 | 1974-03-28 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE2313721A1 (de) | 1973-03-20 | 1974-10-03 | Bayer Ag | Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel |
| DE2413722C3 (de) * | 1974-03-21 | 1982-04-08 | Bayer Ag, 5090 Leverkusen | Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel |
| DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| CA1185974A (en) | 1981-12-03 | 1985-04-23 | Adolf Parg | 1,3,5-triazinones and their use for controlling undesirable plant growth |
| DE3314739A1 (de) | 1983-04-23 | 1984-10-25 | Bayer Ag, 5090 Leverkusen | 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel |
| DE3408768A1 (de) | 1984-03-09 | 1985-09-12 | Bayer Ag, 5090 Leverkusen | Immunstimulierende mittel |
| DE3516631A1 (de) | 1985-05-09 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen |
| DE3516632A1 (de) | 1985-05-09 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 1,3,5-triazintrionen |
| DE3703105A1 (de) | 1987-02-03 | 1988-08-11 | Bayer Ag | Mittel gegen protozoen bei insekten |
| DE3810080A1 (de) | 1988-03-25 | 1989-10-05 | Bayer Ag | Trisubstituierte 1,3,5-triazin-2,4,6-trione |
| DE3814323A1 (de) | 1988-04-28 | 1989-11-09 | Hoechst Ag | Wasserloesliche zubereitungen von coccidiostatica |
| US4933341A (en) | 1988-10-08 | 1990-06-12 | Bayer Aktiengesellschaft | Substituted 1,3,5-triazinetriones, for use against parasitic protozoa |
| DE4000624A1 (de) | 1990-01-11 | 1991-07-18 | Bayer Ag | Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung |
| DE4329096A1 (de) | 1993-08-30 | 1995-03-02 | Bayer Ag | Heterocyclylbenzoheterocyclen |
| US5604180A (en) | 1995-06-02 | 1997-02-18 | Crews, Jr.; Alvin D. | 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| US5519133A (en) | 1995-06-02 | 1996-05-21 | American Cyanamid Co. | 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| US5726126A (en) | 1995-06-02 | 1998-03-10 | American Cyanamid Company | 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents |
| CZ146296A3 (en) | 1995-06-02 | 1997-04-16 | American Cyanamid Co | 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents |
| US5679791A (en) | 1996-07-25 | 1997-10-21 | American Cyanamid Company | 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
| HK1043019B (zh) | 1998-10-08 | 2005-05-13 | 高新研究公司 | 用於预防和治疗原虫病的组合物和方法 |
| CA2356181A1 (en) | 1998-12-22 | 2000-06-29 | Bayer Corporation | Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma |
| DE19937500A1 (de) | 1999-08-09 | 2001-02-15 | Bayer Ag | Substituierte Heterocyclylbenzofurane |
| DE19958388A1 (de) | 1999-12-03 | 2001-06-07 | Bayer Ag | Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten |
| US6444615B1 (en) | 2000-04-18 | 2002-09-03 | Dow Agrosciences Llc | Herbicidal imidazolidinetrione and thioxo-imidazolidinediones |
| DE10034800A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Benzostickstoffheterocyclen |
| DE10040174A1 (de) | 2000-08-17 | 2002-02-28 | Bayer Ag | Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen |
| DE10040110A1 (de) | 2000-08-17 | 2002-02-28 | Bayer Ag | Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen |
| AU2002324586B2 (en) | 2001-08-02 | 2008-04-24 | Neurocrine Biosciences, Inc. | 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| US6861523B2 (en) | 2002-02-08 | 2005-03-01 | Torrey Pines Institute For Molecular Studies | 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries |
| PL372418A1 (en) | 2002-05-30 | 2005-07-25 | Solvay Pharmaceuticals B.V. | 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors |
| JP2005534681A (ja) | 2002-07-15 | 2005-11-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としてのトキソフラビンの３−フラニル類似物 |
| DE102006038292A1 (de) | 2006-08-16 | 2008-02-21 | Bayer Healthcare Ag | Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen |
| WO2008148008A1 (en) * | 2007-05-23 | 2008-12-04 | Emory University | High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity |
| WO2011150347A2 (en) * | 2010-05-28 | 2011-12-01 | Pharmatrophix | Non-peptide bdnf neurotrophin mimetics |
| KR20150134369A (ko) | 2013-03-15 | 2015-12-01 | 파마트로픽스 인코포레이티드 | 비펩타이드 bdnf 뉴로트로핀 모방체 |
| CA2935270A1 (en) | 2014-01-20 | 2015-07-23 | F. Hoffmann-La Roche Ag | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders |
| CN107249349B (zh) | 2014-12-10 | 2021-06-08 | 马斯公司 | 用于调节味觉受体的方法 |
| BR112019012709A2 (pt) | 2016-12-21 | 2019-11-26 | AlzeCure Pharma AB | composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica. |
| MX2020008816A (es) | 2018-02-26 | 2020-09-28 | AlzeCure Pharma AB | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. |
| GB201810669D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
-
2018
- 2018-06-28 GB GBGB1810668.2A patent/GB201810668D0/en not_active Ceased
-
2019
- 2019-06-28 JP JP2020570716A patent/JP7510358B2/ja active Active
- 2019-06-28 CN CN201980045116.8A patent/CN112513032B/zh active Active
- 2019-06-28 CA CA3104237A patent/CA3104237A1/en active Pending
- 2019-06-28 BR BR112020026619-1A patent/BR112020026619A2/pt not_active Application Discontinuation
- 2019-06-28 US US17/255,642 patent/US11840524B2/en active Active
- 2019-06-28 KR KR1020217000575A patent/KR20210024531A/ko active Pending
- 2019-06-28 WO PCT/GB2019/051853 patent/WO2020002950A1/en not_active Ceased
- 2019-06-28 EP EP19739692.2A patent/EP3814335B1/en active Active
- 2019-06-28 ES ES19739692T patent/ES2935183T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530446A5 (enExample) | ||
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| JP2019077725A5 (enExample) | ||
| WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
| US8859768B2 (en) | Heteroaryls and uses thereof | |
| US11753381B2 (en) | Inhibitors of receptor interacting protein kinase I for the treatment of disease | |
| JP2010518026A5 (enExample) | ||
| JP2019515931A5 (enExample) | ||
| SK16242002A3 (sk) | Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje | |
| JP2009525340A5 (enExample) | ||
| CA3214095A1 (en) | Lactams as cbl-b inhibitors | |
| US20120225873A1 (en) | Compounds for alzheimer's disease | |
| US20210317092A1 (en) | Tetrazole containing compounds | |
| TWI869058B (zh) | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 | |
| US8420810B2 (en) | Bicyclic heterocyclic compound | |
| CN115137726B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| JPWO2019178129A5 (enExample) | ||
| JPWO2020002950A5 (enExample) | ||
| JP2009500366A5 (enExample) | ||
| JP6169699B2 (ja) | 脆弱ｘ症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体 | |
| WO2022253943A1 (en) | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide | |
| US20060025448A1 (en) | Hair growth stimulators | |
| RU2021100814A (ru) | 4-замещенные производные фенил-1,3,5-триазина как модуляторы рецепторов trk | |
| JP2002241268A (ja) | 水溶解性が改善された医薬組成物 | |
| IL265242A (en) | Compounds for the treatment of hypertension and / or fibrosis |